{
    "medicine_id": "6aa5b3f8c6852a581ca48a5c44541bd09f2873f9",
    "platform_id": "DB13896",
    "metadata": {
        "name": "Imlygic 1000000 PFU 1mL Injection suspension",
        "composition": "1000000 PFU 1mL Talimogene laherparepvec",
        "clinical_particulars": {
            "therapeutic_indications": "This medication is a genetically modified oncolytic viral therapy indicated for the local treatment of unresectable cutaneous subcutaneous and nodal lesions in patients with melanoma recurrent after initial surgery FDA Label Elsewhere the EMA notes that the agent is indicated for the treatment of adults with unresectable melanoma that is regionally or distantly metastatic Stage IIIB IIIC and IVM1a with no bone brain lung or other visceral diseases L2209",
            "contraindications": {
                "disease": "There is no clinical experience with overdose with talimogene laherparepvec FDA Label L2209 Doses up to 4 mL at a concentration of 10 8 PFU mL every 2 weeks have been administered in clinical trials with no evidence of dose limiting toxicity FDA Label L2209 The maximum dose of talimogene laherparepvec that can be safely administered has not been determined FDA Label L2209 Nevertheless some adverse reactions that are possible from taking talimogene laherparepvec range from fatigue chills pyrexia nausea influenza like illness injection site pain to even injection site complications including cellulitis systemic bacterial infection and others herpetic infection or plasmacytoma at or near the injection site FDA Label L2209 As a result healthcare providers and caregivers must observe the necessary safety precautions when administering talimogene laherparepvec to patients as accidental exposure to the agent can lead to exposure to and transmission of talimogene laherparepvec and herpetic infection in individuals who do not need the medication or in whom the medication is not indicated FDA Label L2209 Moreover in the event of a suspected overdose or inadvertent intravenous administration the patient should be treated symptomatically ie with acyclovir or other anti viral agents and supportive measures instituted as needed FDA Label L2209",
                "pregnancy": "NA",
                "machine_ops": "NA",
                "pharmacodynamics": "Talimogene laherparepvec has been genetically modified to replicate within tumors and to produce the immune stimulatory protein GM CSF granulocyte macrophage colony stimulating factor FDA Label The medication causes lysis of tumors followed by the release of tumor derived antigens which together with virally derived GM CSF may promote an anti tumor immune response in the body FDA Label",
                "excipients": "NA",
                "incompatibilities": [
                    {
                        "drugbank-id": "DB00012",
                        "description": "The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Talimogene laherparepvec"
                    },
                    {
                        "drugbank-id": "DB00016",
                        "description": "The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Talimogene laherparepvec"
                    },
                    {
                        "drugbank-id": "DB08894",
                        "description": "The risk or severity of Thrombosis can be increased when Peginesatide is combined with Talimogene laherparepvec"
                    },
                    {
                        "drugbank-id": "DB09107",
                        "description": "The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol epoetin beta is combined with Talimogene laherparepvec"
                    }
                ]
            }
        },
        "revision_date": "2023-05-14"
    }
}